Randomized Evaluation of Bromocriptine in Myocardial Recovery Therapy (REBIRTH) for Peripartum Cardiomyopathy

Determine the impact of bromocriptine on the improvement in LVEF for women presenting with PPCM.

For more information, please visit: https://clinicaltrials.gov/study/NCT05180773

Inova Fairfax Medical Center 
3300 Gallows Rd  
Falls Church, VA, 22042

1. Presentation with a new diagnosis of peripartum cardiomyopathy.
2. Post-delivery and within the first 5 months post-partum.
3. Clinical assessment of an LVEF < 0.40 within 4 weeks of consent for randomized control trial.
4. Clinical assessment of an LVEF < 0.40 within 8 weeks of consent for breastfeeding cohort.
5. Subject agrees not to breastfeed.

1. Previous diagnosis of cardiomyopathy, valvular disease or complex congenital heart disease (with the exception of women with a history of peripartum cardiomyopathy with complete recovery and a documented LVEF > 0.55 prior to or in early pregnancy.
2. Refractory hypertension (Systolic >160 or Diastolic > 95) either at the time of consent or at the time of the qualifying LVEF.
3. Currently Pregnant.
4. Previous cardiac transplant.
5.  Current history of alcohol or drug abuse.
6. Medical, social or psychiatric condition which limit the ability to comply with follow-up.